Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Yael L. Maxwell

November 28, 2017

News Conference News AHA 2017

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Michael O'Riordan

November 13, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

Shelley Wood

November 02, 2017

News Daily News

NOAC Bleeding Risk Rises With Several Drug Combinations

Michael O'Riordan

October 06, 2017

News Daily News

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

Michael O'Riordan

September 29, 2017

News Conference News ESC 2017

EMANATE: Another NOAC Shown to Be Safe, Effective in the Setting of Cardioversion for A-fib

Todd Neale

September 05, 2017

Podcast TCTMD Talking Points

Episode 28: The AMULET Observational Study

August 23, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Todd Neale

May 05, 2017

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

News Features

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

Shelley Wood

January 04, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Advertisement

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Nephroprotective NOACs? Renal Dysfunction Not Infrequent Among A-fib Patients, but Some Agents Reduce Risk

Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation

Live From Denver: TCT 2017, Day Four

NOAC Bleeding Risk Rises With Several Drug Combinations

No Anticoagulation Benefit, High Bleeding Risk Seen in Patients With Secondary A-fib

EMANATE: Another NOAC Shown to Be Safe, Effective in the Setting of Cardioversion for A-fib

Episode 28: The AMULET Observational Study

Betrixaban Approved for Prevention of VTE

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content